Achondroplasia affects approximately 1 out every 20,000 newborns, and treatment advances for children with this bone growth disorder have been limited.16,17 Children with achondroplasia reach an adult height of 4 feet 10 inches or shorter and may also experience serious, often debilitating health complications.17
FGFR genetic alterations can cause more than 99% of achondroplasia cases.18
Infigratinib is not currently FDA approved for this indication in the U.S. and is not approved for use by any other health authority.
QED Therapeutics is currently looking to enroll children in PROPEL, a prospective clinical assessment study in children with achondroplasia. The study aims to learn more about the overall health, growth, and possible medical complications in children with achondroplasia.
200 boys and girls will participate in the study at locations worldwide. No medication will be administered; however, children successfully enrolled in PROPEL for 6 months or more may be eligible for subsequent treatment trials sponsored by QED Therapeutics.
To be considered for inclusion in the PROPEL Study, children must:
Be 2.5 to 10 years of age at study entry
Have a diagnosis of achondroplasia
Receive agreement from parents or caregivers to have their children participate and follow all study visit schedules and procedures
Other study requirements will be reviewed in detail by the study staff